Coronavirus Vaccine Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 51.23 Billion
CAGR (2026-2031)	3.5%
Fastest Growing Segment	Nucleic Acid Vaccine
Largest Market	North America
Market Size (2031)	USD 62.97 Billion

Market Overview

The Global Coronavirus Vaccine Market is projected to grow from USD 51.23 Billion in 2025 to USD 62.97 Billion by 2031 at a 3.5% CAGR. Coronavirus vaccines are biological preparations designed to elicit an immune response against the SARS-CoV-2 virus, thereby preventing or mitigating COVID-19 disease severity, hospitalization, and mortality through various technological platforms including mRNA, viral vector, inactivated, and protein-based methods. Market growth is primarily driven by the emergence of new viral variants, necessitating updated vaccine formulations, sustained government support for vaccine development and distribution, and substantial investments in research and manufacturing capabilities. Increased demand for booster vaccinations to maintain population immunity further propels market expansion.

According to the World Health Organization's Global Vaccine Market Report, in 2022, COVID-19 vaccines constituted 7.7 billion doses of the 12.7 billion total vaccine doses supplied globally, demonstrating their considerable market volume. A significant challenge impeding global market expansion remains the inequitable distribution of vaccines, leading to disparities in access, particularly impacting lower-income nations.

Key Market Drivers

The ongoing emergence of new viral variants is a primary catalyst driving the Global Coronavirus Vaccine Market, as these mutations necessitate continuous vaccine adaptation to maintain efficacy against evolving strains. This dynamic environment compels pharmaceutical companies to accelerate the development and commercialization of updated vaccine formulations, thereby ensuring sustained demand for protective immunity. The consistent need for variant-adapted vaccines underpins ongoing revenue streams for manufacturers, demonstrating the market’s responsiveness to biological threats. For instance, according to Pfizer Inc., in its February 2026 'Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance' press release, the company expects approximately $5 billion in revenues from its COVID-19 products in 2026, reflecting the continued requirement for these vaccinations to address the persistent viral evolution.

Concurrently, intensified research and development initiatives are a critical determinant of market expansion, propelling advancements in vaccine technology platforms and enabling faster responses to new public health challenges. Pharmaceutical firms are significantly investing in R&D to enhance vaccine stability, improve delivery methods, and explore next-generation preventative solutions, including combination vaccines. These efforts are crucial for extending vaccine protection and preparing for future outbreaks. According to Pfizer Inc., in its December 2024 'Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance' press release, the company anticipated full-year 2025 Adjusted Research and Development expenses to be in the range of $10.7 to $11.7 billion. This substantial investment underscores the commitment to innovation within the sector. Overall, the broader vaccine market continues to demonstrate significant activity; according to Global Health Press, in April 2026, global vaccine production is estimated at approximately 14.5 billion doses annually for 2025 to 2026.

Download Free Sample Report

Key Market Challenges

The inequitable distribution of coronavirus vaccines presents a significant impediment to the sustained growth of the global market. This challenge is rooted in disparities in manufacturing capabilities and access, particularly affecting lower-income nations. These regions often rely heavily on external procurement, which can lead to vulnerabilities in supply chains and inconsistent access.

According to the World Health Organization's Global Vaccine Market Report, in 2024, countries within the WHO African and Eastern Mediterranean regions procured almost entirely, over 95%, of their vaccine doses from manufacturers located outside of their respective regions. This substantial dependence on external supply limits the development of robust regional vaccine markets and production ecosystems. Such reliance can result in delayed vaccine availability and increased logistical complexities, which directly impede consistent immunization programs and sustained market penetration in these populous areas. Consequently, the global market's overall expansion is constrained by the inability to fully leverage demand and establish stable distribution channels across all geographic segments.

Key Market Trends

The emergence of pan-coronavirus vaccine research represents a significant trend aimed at developing broader and more durable protection against current and future SARS-CoV-2 variants, and potentially other coronaviruses. This research endeavors to move beyond the cycle of variant-specific updates by identifying conserved viral targets that elicit a wide-ranging immune response, thereby offering a more stable, long-term solution. This strategic shift towards universal vaccines seeks to minimize the public health impact of emergent strains and reduce logistical complexities. According to CBS News, in May 2025, the National Institutes of Health had previously awarded $62.4 million in grant money to researchers at seven universities working on pan-coronavirus vaccines. This investment underscores the commitment to establishing sustained immunity.

Another pivotal trend shaping the global coronavirus vaccine market is the expansion of non-injectable vaccine formulations, enhancing vaccine accessibility and patient compliance. These alternative delivery methods, such as oral vaccines or nasal sprays, offer advantages by simplifying administration and enabling broader distribution, particularly for populations with needle phobia. Moreover, mucosal vaccines delivered intranasally may induce localized immunity at the primary site of viral entry, offering an additional layer of protection against infection and transmission. According to a specialized news update, 'Accelerating Development for Some NextGen Covid Vaxes', in April 2026, six preclinical reports on mucosal vaccines were noted. This highlights ongoing research and development efforts aimed at more user-friendly and effective vaccination strategies.

Segmental Insights

The Global Coronavirus Vaccine Market is witnessing Nucleic Acid Vaccines as the fastest-growing segment, primarily driven by their inherent advantages in rapid development and manufacturing scalability. This platform allows for swift adaptation to emerging viral variants, a critical factor in pandemic response. Furthermore, significant technological advancements in genetic engineering and delivery systems, such as lipid nanoparticle technology, have enhanced their efficacy and stability. The successful and widespread deployment of mRNA-based vaccines, exemplified by those from Pfizer-BioNTech and Moderna, following emergency use authorizations from regulatory bodies like the U.S. Food and Drug Administration (FDA), has further solidified confidence and investment in this innovative vaccine type.

Regional Insights

North America leads the global coronavirus vaccine market due to its robust public health infrastructure, significant government investment, and advanced biotechnology capabilities. The region benefits from the strong presence of major pharmaceutical companies that invest heavily in research and development and rapid deployment of advanced vaccine technologies, such as mRNA platforms. Additionally, the clear regulatory pathways and accelerated review processes by bodies like the U.S. Food and Drug Administration (FDA) have facilitated quicker vaccine development and approvals, ensuring timely access and widespread adoption across the population.

Recent Developments

In February 2026, South Korean pharmaceutical company SK bioscience initiated clinical testing in Australia for a new vaccine candidate, GBP511. This vaccine represents breakthrough research as it is designed to offer protection against COVID-19 and other related coronaviruses, including those not yet transmitted to humans. The international Phase 1/2 trial, which began enrollment in January 2026, aims to assess the safety and immunogenicity in approximately 368 healthy adults. This development is a significant step towards creating broadly protective sarbecovirus vaccines for pandemic preparedness in the global coronavirus vaccine market.
In January 2026, Novavax, Inc. and Pfizer entered into a license agreement concerning Novavax's Matrix-M® adjuvant technology. Under the terms of this non-exclusive agreement, Pfizer obtained rights to utilize Matrix-M for developing products in up to two disease areas. Novavax received an upfront payment of $30 million and has the potential to receive up to an additional $500 million in development and sales milestones, along with high mid-single-digit percentage royalties. This collaboration signifies a strategic partnership aimed at leveraging innovative adjuvant technology for future vaccine development within the global coronavirus vaccine market.
In August 2025, Novavax, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its Nuvaxovid™ 2025-2026 Formula for preventing COVID-19 in eligible individuals. This protein-based, non-mRNA vaccine became available for the upcoming vaccination season, specifically formulated to target the JN.1 variant, which was the predominant strain globally as of July 2025. Novavax partnered with Sanofi, which leads the commercialization efforts for Nuvaxovid, enabling broader access to this updated vaccine within the global coronavirus vaccine market. The approval reinforces the continued development of diverse vaccine technologies to address evolving viral strains.
In June 2025, Moderna received U.S. Food and Drug Administration (FDA) approval for its next-generation COVID-19 vaccine, mNexspike (mRNA-1283). This updated vaccine was designed to target a specific portion of the SARS-CoV-2 spike protein, allowing for a significantly reduced dose compared to Moderna's original vaccine. Company officials indicated that mNexspike could potentially be refrigerator-stable, which would facilitate easier distribution and administration across various settings. The approval was based on positive Phase 3 clinical trial results and aimed to enhance protection against coronavirus in vulnerable populations.

Key Market Players

Pfizer Inc.
BioNTech SE
Moderna, Inc.
AstraZeneca PLC
Johnson & Johnson Services Inc.
Novavax, Inc.
Sinovac Biotech Ltd.
Sinopharm Group Co., Ltd.
Bharat Biotech International Limited
Serum Institute of India Pvt. Ltd.

By Infection Type	By Vaccine Type	By Product Type	By Route of Administration	By Patient Type	By End User	By Region
SARS-CoV-2 SARS-CoV MERS-CoV	Virus Vaccine Viral Vector Vaccine Nucleic Acid Vaccine Protein Based Vaccine Others	Monovalent Vaccine v/s Multivariant Vaccine	Intramuscular Oral Intranasal	Adults v/s Pediatric	Hospitals Clinics Research Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Coronavirus Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Coronavirus Vaccine Market, By Infection Type:

SARS-CoV-2
SARS-CoV
MERS-CoV

Coronavirus Vaccine Market, By Vaccine Type:

Virus Vaccine
Viral Vector Vaccine
Nucleic Acid Vaccine
Protein Based Vaccine
Others

Coronavirus Vaccine Market, By Product Type:

Monovalent Vaccine v/s Multivariant Vaccine

Coronavirus Vaccine Market, By Route of Administration:

Intramuscular
Oral
Intranasal

Coronavirus Vaccine Market, By Patient Type:

Adults v/s Pediatric

Coronavirus Vaccine Market, By End User:

Hospitals
Clinics
Research Institutes
Others

Coronavirus Vaccine Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Coronavirus Vaccine Market.

Available Customizations:

Global Coronavirus Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Coronavirus Vaccine Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Coronavirus Vaccine Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV)

5.2.2. By Vaccine Type (Virus Vaccine, Viral Vector Vaccine, Nucleic Acid Vaccine, Protein Based Vaccine, Others)

5.2.3. By Product Type (Monovalent Vaccine v/s Multivariant Vaccine)

5.2.4. By Route of Administration (Intramuscular, Oral, Intranasal)

5.2.5. By Patient Type (Adults v/s Pediatric)

5.2.6. By End User (Hospitals, Clinics, Research Institutes, Others)

5.2.7. By Region

5.2.8. By Company (2025)

5.3. Market Map

6. North America Coronavirus Vaccine Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Infection Type

6.2.2. By Vaccine Type

6.2.3. By Product Type

6.2.4. By Route of Administration

6.2.5. By Patient Type

6.2.6. By End User

6.2.7. By Country

6.3. North America: Country Analysis

6.3.1. United States Coronavirus Vaccine Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Infection Type

6.3.1.2.2. By Vaccine Type

6.3.1.2.3. By Product Type

6.3.1.2.4. By Route of Administration

6.3.1.2.5. By Patient Type

6.3.1.2.6. By End User

6.3.2. Canada Coronavirus Vaccine Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Infection Type

6.3.2.2.2. By Vaccine Type

6.3.2.2.3. By Product Type

6.3.2.2.4. By Route of Administration

6.3.2.2.5. By Patient Type

6.3.2.2.6. By End User

6.3.3. Mexico Coronavirus Vaccine Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Infection Type

6.3.3.2.2. By Vaccine Type

6.3.3.2.3. By Product Type

6.3.3.2.4. By Route of Administration

6.3.3.2.5. By Patient Type

6.3.3.2.6. By End User

7. Europe Coronavirus Vaccine Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Infection Type

7.2.2. By Vaccine Type

7.2.3. By Product Type

7.2.4. By Route of Administration

7.2.5. By Patient Type

7.2.6. By End User

7.2.7. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Coronavirus Vaccine Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Infection Type

7.3.1.2.2. By Vaccine Type

7.3.1.2.3. By Product Type

7.3.1.2.4. By Route of Administration

7.3.1.2.5. By Patient Type

7.3.1.2.6. By End User

7.3.2. France Coronavirus Vaccine Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Infection Type

7.3.2.2.2. By Vaccine Type

7.3.2.2.3. By Product Type

7.3.2.2.4. By Route of Administration

7.3.2.2.5. By Patient Type

7.3.2.2.6. By End User

7.3.3. United Kingdom Coronavirus Vaccine Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Infection Type

7.3.3.2.2. By Vaccine Type

7.3.3.2.3. By Product Type

7.3.3.2.4. By Route of Administration

7.3.3.2.5. By Patient Type

7.3.3.2.6. By End User

7.3.4. Italy Coronavirus Vaccine Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Infection Type

7.3.4.2.2. By Vaccine Type

7.3.4.2.3. By Product Type

7.3.4.2.4. By Route of Administration

7.3.4.2.5. By Patient Type

7.3.4.2.6. By End User

7.3.5. Spain Coronavirus Vaccine Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Infection Type

7.3.5.2.2. By Vaccine Type

7.3.5.2.3. By Product Type

7.3.5.2.4. By Route of Administration

7.3.5.2.5. By Patient Type

7.3.5.2.6. By End User

8. Asia Pacific Coronavirus Vaccine Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Infection Type

8.2.2. By Vaccine Type

8.2.3. By Product Type

8.2.4. By Route of Administration

8.2.5. By Patient Type

8.2.6. By End User

8.2.7. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Coronavirus Vaccine Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Infection Type

8.3.1.2.2. By Vaccine Type

8.3.1.2.3. By Product Type

8.3.1.2.4. By Route of Administration

8.3.1.2.5. By Patient Type

8.3.1.2.6. By End User

8.3.2. India Coronavirus Vaccine Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Infection Type

8.3.2.2.2. By Vaccine Type

8.3.2.2.3. By Product Type

8.3.2.2.4. By Route of Administration

8.3.2.2.5. By Patient Type

8.3.2.2.6. By End User

8.3.3. Japan Coronavirus Vaccine Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Infection Type

8.3.3.2.2. By Vaccine Type

8.3.3.2.3. By Product Type

8.3.3.2.4. By Route of Administration

8.3.3.2.5. By Patient Type

8.3.3.2.6. By End User

8.3.4. South Korea Coronavirus Vaccine Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Infection Type

8.3.4.2.2. By Vaccine Type

8.3.4.2.3. By Product Type

8.3.4.2.4. By Route of Administration

8.3.4.2.5. By Patient Type

8.3.4.2.6. By End User

8.3.5. Australia Coronavirus Vaccine Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Infection Type

8.3.5.2.2. By Vaccine Type

8.3.5.2.3. By Product Type

8.3.5.2.4. By Route of Administration

8.3.5.2.5. By Patient Type

8.3.5.2.6. By End User

9. Middle East & Africa Coronavirus Vaccine Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Infection Type

9.2.2. By Vaccine Type

9.2.3. By Product Type

9.2.4. By Route of Administration

9.2.5. By Patient Type

9.2.6. By End User

9.2.7. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Coronavirus Vaccine Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Infection Type

9.3.1.2.2. By Vaccine Type

9.3.1.2.3. By Product Type

9.3.1.2.4. By Route of Administration

9.3.1.2.5. By Patient Type

9.3.1.2.6. By End User

9.3.2. UAE Coronavirus Vaccine Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Infection Type

9.3.2.2.2. By Vaccine Type

9.3.2.2.3. By Product Type

9.3.2.2.4. By Route of Administration

9.3.2.2.5. By Patient Type

9.3.2.2.6. By End User

9.3.3. South Africa Coronavirus Vaccine Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Infection Type

9.3.3.2.2. By Vaccine Type

9.3.3.2.3. By Product Type

9.3.3.2.4. By Route of Administration

9.3.3.2.5. By Patient Type

9.3.3.2.6. By End User

10. South America Coronavirus Vaccine Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Infection Type

10.2.2. By Vaccine Type

10.2.3. By Product Type

10.2.4. By Route of Administration

10.2.5. By Patient Type

10.2.6. By End User

10.2.7. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Coronavirus Vaccine Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Infection Type

10.3.1.2.2. By Vaccine Type

10.3.1.2.3. By Product Type

10.3.1.2.4. By Route of Administration

10.3.1.2.5. By Patient Type

10.3.1.2.6. By End User

10.3.2. Colombia Coronavirus Vaccine Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Infection Type

10.3.2.2.2. By Vaccine Type

10.3.2.2.3. By Product Type

10.3.2.2.4. By Route of Administration

10.3.2.2.5. By Patient Type

10.3.2.2.6. By End User

10.3.3. Argentina Coronavirus Vaccine Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Infection Type

10.3.3.2.2. By Vaccine Type

10.3.3.2.3. By Product Type

10.3.3.2.4. By Route of Administration

10.3.3.2.5. By Patient Type

10.3.3.2.6. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Coronavirus Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Pfizer Inc.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. BioNTech SE

15.3. Moderna, Inc.

15.4. AstraZeneca PLC

15.5. Johnson & Johnson Services Inc.

15.6. Novavax, Inc.

15.7. Sinovac Biotech Ltd.

15.8. Sinopharm Group Co., Ltd.

15.9. Bharat Biotech International Limited

15.10. Serum Institute of India Pvt. Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer

Figures and Tables

List of Figures

Figure 1: Global Coronavirus Vaccine Market Share, By Value (USD Million), 2020-2026F

Figure 2: Global Coronavirus Vaccine Market Share, By Volume (Million Units), 2020-2026F

Figure 3: Global Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 4: Global Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 5: Global Coronavirus Vaccine Market Share, By Product Type, By Value 2020-2026F

Figure 6: Global Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 7: Global Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 8: Global Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 9: Global Coronavirus Vaccine Market Share, Market Map, By Region, By Value, 2020-2026F

Figure 10: North America Coronavirus Vaccine Market Share, By Value (USD Million), 2020-2026F

Figure 11: North America Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 12: North America Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 13: North America Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 14: North America Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 15: North America Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 16: North America Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 17: North America Coronavirus Vaccine Market Share, By Country, By Value, 2020-2026F

Figure 18: United States Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 19: United States Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 20: United States Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 21: United States Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 22: United States Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 23: United States Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 24: Mexico Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 25: Mexico Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 26: Mexico Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 27: Mexico Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 28: Mexico Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 29: Mexico Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 30: Canada Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 31: Canada Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 32: Canada Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 33: Canada Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 34: Canada Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 35: Canada Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 36: Europe Coronavirus Vaccine Market Share, By Value (USD Million), 2020-2026F

Figure 37: Europe Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 38: Europe Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 39: Europe Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 40: Europe Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 41: Europe Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 42: Europe Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 43: Europe Coronavirus Vaccine Market Share, By Country, By Value, 2020-2026F

Figure 44: United Kingdom Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 45: United Kingdom Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 46: United Kingdom Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 47: United Kingdom Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 48: United Kingdom Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 49: United Kingdom Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 50: Germany Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 51: Germany Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 52: Germany Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 53: Germany Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 54: Germany Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 55: Germany Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 56: France Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 57: France Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 58: France Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 59: France Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 60: France Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 61: France Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 62: Italy Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 63: Italy Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 64: Italy Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 65: Italy Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 66: Italy Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 67: Italy Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 68: Spain Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 69: Spain Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 70: Spain Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 71: Spain Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 72: Spain Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 73: Spain Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 74: APAC Coronavirus Vaccine Market Share, By Value (USD Million), 2020-2026F

Figure 75: APAC Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 76: APAC Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 77: APAC Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 78: APAC Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 79: APAC Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 80: APAC Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 81: APAC Coronavirus Vaccine Market Share, By Country, By Value, 2020-2026F

Figure 82: China Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 83: China Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 84: China Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 85: China Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 86: China Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 87: China Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 88: India Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 89: India Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 90: India Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 91: India Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 92: India Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 93: India Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 94: Singapore Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 95: Singapore Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 96: Singapore Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 97: Singapore Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 98: Singapore Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 99: Singapore Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 100: Japan Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 101: Japan Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 102: Japan Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 103: Japan Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 104: Japan Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 105: Japan Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 106: South Korea Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 107: South Korea Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 108: South Korea Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 109: South Korea Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 110: South Korea Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 111: South Korea Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 112: Hong Kong Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 113: Hong Kong Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 114: Hong Kong Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 115: Hong Kong Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 116: Hong Kong Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 117: Hong Kong Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 118: Australia Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 119: Australia Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 120: Australia Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 121: Australia Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 122: Australia Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 123: Australia Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 124: Thailand Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 125: Thailand Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 126: Thailand Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 127: Thailand Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 128: Thailand Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 129: Thailand Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 130: South America Coronavirus Vaccine Market Share, By Value (USD Million), 2020-2026F

Figure 131: South America Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 132: South America Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 133: South America Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 134: South America Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 135: South America Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 136: South America Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 137: South America Coronavirus Vaccine Market Share, By Country, By Value, 2020-2026F

Figure 138: Brazil Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 139: Brazil Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 140: Brazil Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 141: Brazil Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 142: Brazil Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 143: Brazil Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 144: Argentina Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 145: Argentina Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 146: Argentina Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 147: Argentina Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 148: Argentina Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 149: Argentina Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 150: Colombia Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 151: Colombia Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 152: Colombia Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 153: Colombia Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 154: Colombia Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 155: Colombia Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 156: MEA Coronavirus Vaccine Market Share, By Value (USD Million), 2020-2026F

Figure 157: MEA Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 158: MEA Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 159: MEA Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 160: MEA Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 161: MEA Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 162: MEA Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 163: MEA Coronavirus Vaccine Market Share, By Country, By Value, 2020-2026F

Figure 164: UAE Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 165: UAE Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 166: UAE Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 167: UAE Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 168: UAE Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 169: UAE Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 170: Saudi Arabia Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 171: Saudi Arabia Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 172: Saudi Arabia Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 173: Saudi Arabia Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 174: Saudi Arabia Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 175: Saudi Arabia Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 176: Kuwait Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 177: Kuwait Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 178: Kuwait Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 179: Kuwait Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 180: Kuwait Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 181: Kuwait Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Figure 182: South Africa Coronavirus Vaccine Market Share, By Infection Type, By Value, 2020-2026F

Figure 183: South Africa Coronavirus Vaccine Market Share, By Vaccine Type, By Value, 2020-2026F

Figure 184: South Africa Coronavirus Vaccine Market Share, By Product Type, By Value, 2020-2026F

Figure 185: South Africa Coronavirus Vaccine Market Share, By Route of Administration, By Value, 2020-2026F

Figure 186: South Africa Coronavirus Vaccine Market Share, By Patient Type, By Value, 2020-2026F

Figure 187: South Africa Coronavirus Vaccine Market Share, By End User, By Value, 2020-2026F

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Coronavirus Vaccine Market in 2025?

Which is the dominating region in the Global Coronavirus Vaccine Market?

Which is the fastest growing segment in the Global Coronavirus Vaccine Market?

What is the expected growth rate of the Global Coronavirus Vaccine Market?